Methylene blue is a potent and broad-spectrum inhibitor against Zika virus in vitro and in vivo.

Methylene blue is a potent and broad-spectrum inhibitor against Zika virus in vitro and in vivo.
复制标题

DOI:
10.1080/22221751.2020.1838954
复制
发表时间:
2020-12
影响因子:
13.2
通讯作者:
Li H
Li H
中科院分区:
医学2区
文献类型:
--
作者:
Li Z;Lang Y;Sakamuru S;Samrat S;Trudeau N;Kuo L;Rugenstein N;Tharappel A;D'Brant L;Koetzner CA;Hu S;Zhang J;Huang R;Kramer LD;Butler D;Xia M;Li H

文献摘要

参考文献

被引文献

相似文献

许多黄病毒包括登革病毒(DENV)、寨卡病毒(ZIKV)、西尼罗河病毒、黄热病病毒和日本脑炎病毒是重要的人类病原体,不幸的是没有任何特异性治疗。在这里,我们证明了亚甲蓝,一种FDA批准的药物,是一种广谱和有效的抗病毒药物,可以在体外和体内对抗寨卡病毒和登革热病毒。我们发现亚甲基蓝可以显着抑制病毒蛋白酶NS 3及其NS 2B辅因子之间的相互作用,抑制病毒蛋白酶活性,抑制病毒生长,保护3D迷你脑类器官免受ZIKV感染,并减少小鼠模型中的病毒血症。机制研究证实,亚甲蓝在进入和进入后步骤中起作用,减少复制子细胞中的病毒产生并抑制加工的NS3蛋白的产生。总的来说,我们已经证明亚甲蓝是一种有效的抗病毒药物,用于管理黄病毒感染,特别是寨卡病毒。作为FDA批准的药物,亚甲蓝对人类使用耐受良好。因此,亚甲蓝代表了用于管理ZIKV和其他黄病毒感染的有前景且容易开发的疗法。
Many flaviviruses including the Dengue virus (DENV), Zika virus (ZIKV), West Nile virus, Yellow Fever virus, and Japanese encephalitis virus are significant human pathogens, unfortunately without any specific therapy. Here, we demonstrate that methylene blue, an FDA-approved drug, is a broad-spectrum and potent antiviral against Zika virus and Dengue virus both in vitro and in vivo. We found that methylene blue can considerably inhibit the interactions between viral protease NS3 and its NS2B co-factor, inhibit viral protease activity, inhibit viral growth, protect 3D mini-brain organoids from ZIKV infection, and reduce viremia in a mouse model. Mechanistic studies confirmed that methylene blue works in both entry and post entry steps, reduces virus production in replicon cells and inhibited production of processed NS3 protein. Overall, we have shown that methylene blue is a potent antiviral for management of flavivirus infections, particularly for Zika virus. As an FDA-approved drug, methylene blue is well-tolerated for human use. Therefore, methylene blue represents a promising and easily developed therapy for management of infections by ZIKV and other flaviviruses.
DOI: 10.3201/eid1705.101939
发表时间: 2011-05
影响因子: 11.8
作者:
Foy BD;Kobylinski KC;Chilson Foy JL;Blitvich BJ;Travassos da Rosa A;Haddow AD;Lanciotti RS;Tesh RB
通讯作者: Tesh RB
DOI: 10.1038/cr.2017.88
发表时间: 2017-08-01
期刊: CELL RESEARCH
影响因子: 44.1
作者:
Li, Zhong;Brecher, Matthew;Li, Hongmin
通讯作者: Li, Hongmin
DOI: 10.2807/1560-7917.es.2016.21.2.30107
发表时间: 2016-01-01
期刊: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
影响因子: --
作者:
Korhonen, Essi Marjana;Huhtamo, Eili;Vapalahti, Olli
通讯作者: Vapalahti, Olli
DOI: 10.1128/jvi.00698-17
发表时间: 2017-08-01
影响因子: 5.4
作者:
Fulton, Benjamin O.;Sachs, David;Evans, Matthew J.
通讯作者: Evans, Matthew J.
DOI: 10.1016/j.antiviral.2017.12.018
发表时间: 2018-03
期刊: Antiviral research
影响因子: 7.6
作者:
Li Z;Sakamuru S;Huang R;Brecher M;Koetzner CA;Zhang J;Chen H;Qin CF;Zhang QY;Zhou J;Kramer LD;Xia M;Li H
通讯作者: Li H